Related Experiment Video
Updated: Apr 20, 2026
07:50
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
16.7K
Harmonization of detailed clinical models with clinical study data standards
1Guoqian Jiang, MD, PhD, Department of Health Sciences Research, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA,
Methods of Information in Medicine
|November 27, 2014
Summary
This study harmonizes Detailed Clinical Models (DCMs) from the SHARPn project with Clinical Data Interchange Standards Consortium (CDISC) standards. This effort aims to improve data sharing and semantic interoperability between clinical research and electronic health record systems.
Area of Science:
- Health Informatics
- Clinical Data Standards
- Interoperability in Health Systems
Background:
- Data sharing between clinical research and EHR systems presents significant challenges.
- Detailed Clinical Models (DCMs) and specific implementations like SHARPn CEMs are emerging solutions.
- Harmonizing these models is crucial for effective data integration.
Purpose of the Study:
- To describe preliminary efforts in harmonizing SHARPn CEMs with CDISC standards.
- To facilitate semantic interoperability for clinical research and secondary data use.
- To address complexity in health systems through data standardization.
Main Methods:
- Focused on three core domains: demographics, lab tests, and medications.
- Conducted a panel review of data elements from CDISC templates and SHARPn CEMs.
- Compared data elements for commonality and identified harmonization issues.
Main Results:
- Identified common data elements applicable to both clinical studies and EHR secondary use.
- Highlighted outstanding issues requiring further harmonization efforts.
- Established a foundation for improved data consistency across systems.
Conclusions:
- Outcomes can inform new requirements for the DCM modeling community.
- Facilitates semantic interoperability between clinical research and EHR systems.
- Supports broader secondary use of patient data while maintaining research integrity.
Related Concept Videos
01:15Methods of Documentation VI: Case Management Model
1.1K
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
1.1K
01:15Model Approaches for Pharmacokinetic Data: Physiological Models
363
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
363
01:16Clinical Trials
11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.2K
01:11Clinical Trials: Overview
5.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.6K
01:27Pharmacodynamic Models: Overview
134
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
134
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
286
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
286